| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| Galena Biopharma (GALE) Withdraws S-3 Registration; Shares Moving Higher | | 8 | StreetInsider.com |
| 22.05.
| Galena Biopharma's Breast Cancer Vaccine Sprouts More Red Flags | | 7 | The Street |
| 21.05.
| Galena Biopharma With Near Term ASCO Catalyst | | 6 | Seeking Alpha |
| 21.05.
| Biotech Industry Booming in 2012 / The Paragon Report Provides Stock Research on Galena Biopharma and Cadence Pharmaceuticals | | 39 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/21/12 -- The Biotechnology Industry has shown investors some impressive gains this year. The SPDR S&P Biotech ETF (XBI) is up nearly 25 percent year-to-date. A flurry...
Mehr lesen zu:
Biotech Industry Booming in 2012 / The Paragon Report Provides Stock Research on Galena Biopharma and Cadence Pharmaceuticals | |
| 10.05.
| Galena Biopharma Notified That RXi Pharmaceuticals' Common Stock to Commence Trading Under Ticker Symbol "RXII" | | 13 | Benzinga.com |
| 10.05.
| RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer | | 35 | Business Wire |
| RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that
Geert Cauwenbergh, Dr. Med. Sc. has been appointed as the Company's
President and Chief Executive...
Mehr lesen zu:
RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer | |
| 10.05.
| RXi Pharmaceuticals' Common Stock to Commence Trading under the Symbol "RXII" | | 43 | Business Wire |
| Public Listing Marks Completion of Spin-off into Independent,
Publicly-Traded Company
RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) announced today...
Mehr lesen zu:
RXi Pharmaceuticals' Common Stock to Commence Trading under the Symbol "RXII" | |
| 07.05.
| Galena Biopharma: Late Stage NeuVax Justifies Higher Valuation | | 11 | Seeking Alpha |
| 01.05.
| Galena Biopharma (GALE) Gets U.S. Patent Allowance for FBP Peptide Variants | | 7 | StreetInsider.com |
| 30.04.
| XFRA CAPITAL ADJUSTMENT INFORMATION - 30.04.2012 - 2 | | 130 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 30.04.2012 EX KAPITALMASSNAHME GEHANDELT.
THE FOLLOWING SHARES ARE TRADED EX CAPITAL ADJUSTMENT ON 30.04.2012.
INSTR EXCH ISIN INSTRUMENT NAME
RXK XFRA US3632561086...
Mehr lesen zu:
XFRA CAPITAL ADJUSTMENT INFORMATION - 30.04.2012 - 2 | |
| 27.04.
| XFRA RXK: AUSSETZUNG/SUSPENSION | | 39 | Xetra Newsboard |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
Galena Biopharma RXK US3632561086 BAW/UFN
Mehr lesen zu:
XFRA RXK: AUSSETZUNG/SUSPENSION | |
| 24.04.
| Large Pharmaceuticals Look to Smaller Biotech Companies to Combat Losses From Expiring Patents / The Paragon Report Provides Stock Research on Dendreon Corporation and Galena Biopharma | | 51 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 04/24/12 -- Mergers and Acquisitions have been a hot topic in the Biotechnology Industry recently. Pharmaceutical giants face an unprecedented number of patent expirations...
Mehr lesen zu:
Large Pharmaceuticals Look to Smaller Biotech Companies to Combat Losses From Expiring Patents / The Paragon Report Provides Stock Research on Dendreon Corporation and Galena Biopharma | |
| 16.04.
| Galena Biopharma Announces Exercise of Underwriters' Over-Allotment Option and Closing of $14.5 Million Public Offering of Common Stock | | 6 | Benzinga.com |
| 16.04.
| Galena Biopharma (GALE) Closes 9.75M Common Offering | | 2 | StreetInsider.com |
| 09.04.
| Rodman & Renshaw, LLC Acts as a Co-Manager for Galena Biopharma in its Public Offering of Common Stock | | 45 | Business Wire |
| Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman &
Renshaw Capital Group, Inc. (NASDAQ: RODM) announced that it has acted
as a Co-Manager for its client Galena...
Mehr lesen zu:
Rodman & Renshaw, LLC Acts as a Co-Manager for Galena Biopharma in its Public Offering of Common Stock | |
| 04.04.
| Galena Biopharma Announces Public Offering of Common Stock | | 4 | Benzinga.com |
| 23.03.
| Galena Biopharma and CytRx Corp Look to Benefit From Accelerated Approval Pathways / The Paragon Report Provides Equity Research on Galena Biopharma & CytRX | | 59 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 03/23/12 -- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation out of Washington boosts the sector's reach....
Mehr lesen zu:
Galena Biopharma and CytRx Corp Look to Benefit From Accelerated Approval Pathways / The Paragon Report Provides Equity Research on Galena Biopharma & CytRX | |
| 20.03.
| Galena Biopharma (GALE) Receives Notice of Allowance for US Patent Related to NeuVax | | 6 | StreetInsider.com |
| 14.02.
| Galena Biopharma (GALE) Initiates E39 Phase 1/2 in Two Gynecological Cancers | | 2 | StreetInsider.com |
| 20.01.
| Galena Biopharma (GALE) Initiates NeuVax Phase 3 | | 9 | StreetInsider.com |
